Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study Comparing HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Chemotherapy With Pembrolizumab Plus Chemotherapy as the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer.

NCT04750083 is registered in ClinicalTrials.gov with Taizhou Hanzhong biomedical co. LTD as lead sponsor.

NCT NCT04750083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04750083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study Comparing HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Chemotherapy With Pembrolizumab Plus Chemotherapy as the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer.
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 25, 2020
Completion date
September 25, 2023
Enrollment
700 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

nonsquamous non-small cell lung cancer